Winkelmand

Geen producten in de winkelwagen.

OncoLize – Localized cancer medicine: “Treating tumors from the Inside”

OncoLize just landed the first step of €1.6 million to battle pancreatic cancer and lung cancer.

ONCOLIZE BV – “Treating Tumors from the Inside”

OncoLize BV (Leiden, the Netherlands) develops injectable drug depots based on anti-cancer drugs for local and slow release of the drugs inside solid tumors. The company has a highly experienced founders’ team and based on initial preclinical success, it is preparing a Series A of €8 Mln for 2024 to start clinical trials in pancreatic tumors and other aggressive tumor diseases with the highest unmet needs.

Why localized delivery? Solid tumors represent 90% of all cancers, of which 70% is still local/regional at 1st diagnosis. Current delivery methods deliver thru the whole body, dosing drugs to what the patient can withstand, and crippling the immune- and hormone systems that are most important to deal with the disease. Despite the progress with expensive immune-oncology drugs, small molecule drugs, peptides and generic Chemo are here to stay for the coming decades.

Three USP’s that the OncoLize products offer over oral or intravenous delivery of cancer medicine drive for success:
1. Higher efficacy – up to 100x higher drug concentrations at the tumor target.
2. Far less side effects – up to 300x lower total drug dose, up to 1000x lower drug-levels in circulation.
3. We develop Triple A solutions: Affordable and Accessible to All and still with attractive margins and ROI’s.

The OncoLize platform offers a broad range of polymer/drug/buffer formulations, which are produced by straight-forward mixing of well-known pharmaceutical excipients. The depot can load and deliver both soluble and non-soluble small molecule drugs and peptides. The formulations are injected straight into the tumor with thin needles or by image-guided catheters or endoscopes. Once injected, they form semi-solid depots within seconds. The depot gradually dissolves and releases its drug-cargo inside the tumor from days to weeks, as designed. The depots are visible under CT and US for image-guided injection. Furthermore, the technology platform offers short development cycles, excellent CMC-and scale-up features and has been demonstrated in human NSCLC- and Pancreatic tumor cell lines in non-clinical settings. Patents have been granted in the USA (2022) and in final stages in EU-CHN-JPN.

[email protected]
[email protected]

Home